EQS-News: Redcare Pharmacy confirms full-year guidance following sustained positive Q3 sales performance in both Rx and non-Rx.
|
EQS-News: Redcare Pharmacy N.V.
/ Key word(s): Development of Sales/Preliminary Results
Redcare Pharmacy confirms full-year guidance following sustained positive Q3 sales performance in both Rx and non-Rx.
Sevenum, the Netherlands, 6 October 2025. Redcare Pharmacy N.V. today announced its preliminary and unaudited third quarter sales numbers. The Group’s total sales increased 25.2% to EUR 719 million (Q3 2024: EUR 575 million). Both reporting segments, DACH and International, achieved over 25% fully organic sales growth in Q3, 25.2% and 25.4% respectively. Non-Rx sales increased 16.7% to EUR 448 million (Q3 2024: EUR 383 million) and total Rx sales 42.3% to EUR 272 million (Q3 2024: EUR 191 million). In Germany, Rx sales totaled EUR 126 million, an increase of 82.1% year over year (Q3 2024: EUR 69 million). At the end of the quarter, Redcare Pharmacy recorded 13.7 million active customers and a significant improvement in the net promoter score (NPS) to well over 70, vs. 64 in H1 of the current year. Redcare Pharmacy’s CEO Olaf Heinrich comments: “We are delivering strong Q3 momentum, especially in German Rx where we grew double-digits quarter over quarter, and confirm full-year guidance. Growth remains profitable and cash generative, with a solid Q3 EBITDA, lifting our year-to-date margin already to our full-year guidance range of 2 to 2.5%.” Strong momentum in Rx. Entering Q4 with accelerated Rx growth in Germany and the customary seasonal uplift in order volumes in the final quarter of the year, the Group remains on track to achieve at least EUR 500 million Rx sales for the year. Accordingly, Redcare Pharmacy reaffirms its full-year guidance for Rx, as well as for all other elements. Sales by reporting segments. Sales in the DACH segment (Germany, Austria and Switzerland) increased 25.2% in Q3 to EUR 587 million (Q3 2024: EUR 469 million). Non-Rx sales grew 13.4% to EUR 315 million (Q3 2024: EUR 278 million), while prescription medication sales (Rx) grew 42.3% to EUR 272 million (Q3 2024: EUR 191 million). Year to date, total sales were EUR 1.74 billion, up 26.7% versus last year. In the International segment (Belgium, Italy, France and the Netherlands) sales also maintained a fast pace of growth, increasing 25.4% to EUR 132 million (Q3 2024: EUR 105 million). Year to date, sales were EUR 402 million, up 25.9% versus last year.
All published figures are preliminary and unaudited. Redcare Pharmacy N.V. will release the full interim report for the third quarter of 2025 on 29 October 2025. Investor Relations Contact: Monica Ambrosi (Associate Director, Investor Relations) investors@redcare-pharmacy.com
Press Contact: Sven Schirmer (Director, Corporate Communications)
About Redcare Pharmacy. Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven. As the one-stop pharmacy of the future, Redcare Pharmacy offers over 13 million active customers a wide range of more than 250,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products (BPC) as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management. Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.
06.10.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2208236 |
| End of News | EQS News Service |
|
|
2208236 06.10.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 701,01 | 968,06 | 1.060,32 | 1.204,35 | 1.798,76 | 2.370,58 | 3.000,00 | |
| EBITDA1,2 | -18,58 | 15,20 | -38,73 | -29,66 | 39,99 | 29,23 | 63,00 | |
| EBITDA-Margin3 | -2,65 | 1,57 | -3,65 | -2,46 | 2,22 | 1,23 | 2,10 | |
| EBIT1,4 | -33,45 | -0,87 | -65,70 | -69,17 | -17,30 | -38,99 | -8,00 | |
| EBIT-Margin5 | -4,77 | -0,09 | -6,20 | -5,74 | -0,96 | -1,65 | -0,27 | |
| Net Profit (Loss)1 | -36,27 | -16,77 | -74,19 | -77,65 | -11,61 | -46,36 | -19,00 | |
| Net-Margin6 | -5,17 | -1,73 | -7,00 | -6,45 | -0,65 | -1,96 | -0,63 | |
| Cashflow1,7 | -30,37 | 17,80 | 11,64 | -29,11 | 61,46 | 22,13 | 28,00 | |
| Earnings per share8 | -2,78 | -1,17 | -4,15 | -4,32 | -0,73 | -2,27 | -0,92 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Redcare Pharmacy | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2AR94 | NL0012044747 | N.V. | 1.303,64 Mio € | 13.10.2016 | Kaufen | 9F3893WC+F5 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 40,87 | 0,00 | 0,00 | -29,07 | 2,69 | 58,92 | 0,55 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 15.04.2026 | 06.05.2026 | 29.07.2026 | 28.10.2025 | 04.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -13,73% | -35,42% | -52,26% | -59,08% | +126,25% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
